Memantine

Biotech Industry Veterans Jeff Jonas and Al Robichaud Join Cure Ventures as Partners

Retrieved on: 
Monday, January 8, 2024
Biotechnology, Finance, Health, Professional Services, Asset Management, Ionis Pharmaceuticals, Science, Cure, Drug discovery, Partner, Pramipexole, UC, Juno Therapeutics, Forest Laboratories, DSM-IV codes, Heart, Therapy, Memantine, Growth, Central nervous system, Patient, Organization, Harvard Medical School, Biogen, University of California, Irvine, Pharmaceutical industry

Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.

Key Points: 
  • Cure Ventures (“Cure”), a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, today announced the appointment of industry leaders Jeff Jonas, M.D.
  • and Al Robichaud, Ph.D. as partners to expand the firm’s work with biotech entrepreneurs in developing therapeutics that cure life-altering diseases.
  • It’s clear to me that Cure has the chops to strategically choose its partners and elevate their work.
  • More importantly, he is about as well respected a leader as you can find in our industry,” said Dave Fallace, co-founder and managing partner at Cure Ventures.

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

Retrieved on: 
Thursday, November 9, 2023
Alzheimer's disease, PubMed, Rivastigmine, Brain, OTCQB, Food, Ageing, Memantine, Disease, Alzheimer's Disease International, FDA, ADI, Dementia, NIH, AMD, Alzheimer's Association, Macular degeneration, Donepezil, United States patent law, Bangladesh Technical Education Board, Galantamine, Injection, Life, Pharmaceutical industry

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.

Key Points: 
  • PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
  • There are two forms of the disease; wet AMD and dry AMD.
  • ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
  • The Company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.

Delix Presents Interim Data From Phase I Trial of Novel Neuroplastogen at ACNP Annual Meeting

Retrieved on: 
Wednesday, December 6, 2023
Biotechnology, Pharmaceutical, General Health, Health, Mental Health, Genetics, Clinical Trials, Other Health, CNS, Psilocybin, Bowdle, South Dakota, DMT, Phase 1, Therapy, DSM-IV codes, Prefrontal cortex, Plasma, Food, CSF, SAD, Hallucination, Patient, Memantine, Neuron, American College, Pharmacokinetics, Science, Cardiotoxicity, Mysticism, MD, Drug discovery, Psychiatry, Coronavirus Scientific Advisory Board, Ketamine, Drug development, Traffic barrier, Pharmaceutical industry, Generic drug, Vaccine, Medical imaging, Ramipril, Allopregnanolone, Safety

Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.

Key Points: 
  • Delix Therapeutics , a clinical-stage neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological disorders, today announced interim results from the Phase 1 trial evaluating DLX-001, a novel neuroplastogen, in healthy volunteers, which were presented at the 2023 American College of Neuropsychopharmacology (ACNP) Annual Meeting in Tampa, Florida.
  • “Delix is excited to share these data from DLX-001, the first novel neuroplastogen to enter clinical testing.
  • These data reinforce the potential of our broader neuroplastogen platform to develop therapies that can repair damaged neurons,” said Delix CEO Mark Rus.
  • I look forward to leveraging his considerable experiences as we progress our novel neuroplastogen platform and build Delix into a leading neuroscience company."

VectivBio Publishes Invitation to the Annual General Meeting

Retrieved on: 
Wednesday, May 10, 2023
Exercise, Computershare, Proxy, EDT, CEST, Annual general meeting, Rare-earth element, Auction, Memantine

BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2023 Annual General Meeting, which will be held on Thursday, June 1, 2023, at 3:00 p.m. CEST / 9:00 a.m. EDT at Memox (meeting room "Small Space"), Elisabethenstrasse 15, 4051 Basel, Switzerland.

Key Points: 
  • BASEL, Switzerland, May 10, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the invitation to the 2023 Annual General Meeting, which will be held on Thursday, June 1, 2023, at 3:00 p.m. CEST / 9:00 a.m. EDT at Memox (meeting room "Small Space"), Elisabethenstrasse 15, 4051 Basel, Switzerland.
  • Shareholders entered in the company's share register with the right to vote as of May 2, 2023, at 10:00 p.m. CEST / 4:00 p.m. EDT will be entitled to participate in the 2023 Annual General Meeting.
  • Shareholders may also be represented at the 2023 Annual General Meeting by the independent proxy or their proxy, who does not need to be a shareholder, by completing and signing a proxy form.
  • For further information on how to attend the 2023 Annual General Meeting, to exercise rights, to issue voting instructions to the independent proxy or to grant proxy, shareholders can access the invitation to the 2023 Annual General Meeting at www.edocumentview.com/VECT .

CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)

Retrieved on: 
Friday, April 28, 2023
Cognition, CSE, Traumatic brain injury, LE, Memantine, Rivastigmine, Disclosure, Donepezil, Patient, Concussion, Cognitive deficit, Pharmaceutical industry, Department store

Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - Le 28 avril/April 2023) - The common shares and warrants of Alpha Cognition Inc. have been approved for listing on the CSE.
  • Listing and disclosure documents will be available at www.thecse.com on the trading date.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options.
  • Les actions ordinaires et les bons de souscription d'Alpha Cognition Inc. ont été approuvés pour inscription à la CSE.

VectivBio Reports Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, April 19, 2023
SBS, Partnering, Nutrition, Study, Anatomy, AKP, Short bowel syndrome, Pharmacokinetics, Woman, AGM, Memantine, HSCT, EDT, CIC, Trial of the century, Comet, EUR, Methylmalonic acidemia, STARS, Patient, Propionic acidemia, Stoma, CEST, Research, FDA, IND, Telax Hosted Call Center, MMA, Safety, Cryptocurrency, Pharmaceutical industry, Rare-earth element, Vaccine, Q2

ET

Key Points: 
  • ET
    BASEL, Switzerland, April 19, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today reported financial results and provided a business update for the full year ended December 31, 2022.
  • “2022 was a very good year for VectivBio as we made significant progress against our R&D and corporate objectives, despite the challenging biotech environment.
  • In November 2022, the Company announced the completion of enrollment of the Colon-in-Continuity (CIC) stratum of the Phase 3 STARS study.
  • The Company will discuss these results on a call today, April 19, 2023, at 8:00 a.m.

Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published

Retrieved on: 
Tuesday, April 4, 2023
Priority review, Plaque, CET, MHLW, Marketing, Advisory Committee, Memantine, Food, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Lecanemab, Clinical trial, Quality of life, Ministry of Health, Labour and Welfare, Brain, Alzheimer's disease, SOC, MCI, Medication, Pharmaceuticals and Medical Devices Agency, Advisory Committee on Immunization Practices, EMA, Clarity, Ministry, Eisai, Prescription Drug User Fee Act, HIV disease progression rates, Patient, Standard of care, PMDA, National Medical Products Administration, Co-promotion, PDUFA, Ministry of Health (Kuwait), Neurology, MAA, AD, FDA, BLA, NMPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Caregiver, Safety, Pharmaceutical industry, Biogen, Health

A subgroup analysis suggested that earlier initiation of treatment with lecanemab may have a greater impact on disease progression.

Key Points: 
  • A subgroup analysis suggested that earlier initiation of treatment with lecanemab may have a greater impact on disease progression.
  • This paper has been revised to incorporate data from the Phase 3 Clarity AD clinical trial, replacing the previous simulation of long-term health outcomes which relied on results from the Phase 2b clinical trial, published in April 2022.
  • The analysis is based on a disease simulation model (AD ACE model[3]) that used data from the Phase 3 Clarity AD clinical trial, which evaluated the efficacy and safety of lecanemab, and published literature to simulate the natural progression of AD.
  • The U.S. Food and Drug Administration (FDA) determined that the results of Clarity AD can serve as the confirmatory study to verify the clinical benefit of lecanemab.

Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published

Retrieved on: 
Tuesday, April 4, 2023
Priority review, Plaque, CET, MHLW, Marketing, Advisory Committee, Memantine, Food, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Lecanemab, Clinical trial, Quality of life, Ministry of Health, Labour and Welfare, Brain, Alzheimer's disease, SOC, MCI, Medication, Pharmaceuticals and Medical Devices Agency, Advisory Committee on Immunization Practices, EMA, Clarity, Ministry, Eisai, Prescription Drug User Fee Act, HIV disease progression rates, Patient, Standard of care, PMDA, National Medical Products Administration, Co-promotion, PDUFA, Ministry of Health (Kuwait), Neurology, MAA, AD, FDA, BLA, NMPA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Caregiver, Safety, Pharmaceutical industry, Biogen, Health

A subgroup analysis suggested that earlier initiation of treatment with lecanemab may have a greater impact on disease progression.

Key Points: 
  • A subgroup analysis suggested that earlier initiation of treatment with lecanemab may have a greater impact on disease progression.
  • This paper has been revised to incorporate data from the Phase 3 Clarity AD clinical trial, replacing the previous simulation of long-term health outcomes which relied on results from the Phase 2b clinical trial, published in April 2022.
  • The analysis is based on a disease simulation model (AD ACE model[3]) that used data from the Phase 3 Clarity AD clinical trial, which evaluated the efficacy and safety of lecanemab, and published literature to simulate the natural progression of AD.
  • The U.S. Food and Drug Administration (FDA) determined that the results of Clarity AD can serve as the confirmatory study to verify the clinical benefit of lecanemab.

Global Alzheimer's Disease Therapeutics Market Research Report 2023: A $7.16 Billion Market by 2028 - 150+ Assets in Various Development Phases - Epidemiology & Pipeline Analysis - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 28, 2023
Pharmaceutical, Health, Neurology, Magnetic resonance imaging, USFDA, Galantamine, Dementia, Therapy, MAA, Geography, Biogen, Eli Lilly and Company, Safety, Rivastigmine, Magnetism, Deficit spending, Research, Patient, MRI, Neurodegenerative disease, Sleep, AD, Central nervous system, Computerize, Food, Phase, Knowledge, Marketing Authorisation Application, Moa, Enzyme inhibitor, Investment, CT, Growth, PET, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Prevalence, Cassava Sciences, Clinical trial, Memantine, European Medicines Agency, FDA, NMDA, Amnesia, Forgetting, EMA, Pharmaceutical industry, Medicinal plants, Medical imaging, Alzheimer's disease, Donepezil, Epidemiology, Aducanumab

The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market.

Key Points: 
  • The increasing prevalence of Alzheimer's disease is driving the growth of the global Alzheimer's disease therapeutics market.
  • The Alzheimer's disease therapeutics market portfolio contains a total of 151+ assets in various development phases.
  • The Alzheimer's disease therapeutics market has been witnessing considerable growth, which is attributed to the increasing prevalence of Alzheimer's Disease worldwide.
  • The global Alzheimer's disease therapeutics market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating Alzheimer's Disease.

AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy

Retrieved on: 
Tuesday, February 28, 2023
ADAS-Cog, Safety, Scientific Committee on Oceanic Research, Memantine, B cell, ALS, ADAS, Disease, Drug development, Enzyme inhibitor, Marine Institute of Memorial University of Newfoundland, Research, Patient, Cognition, Science, Multiple sclerosis, Memory, Journal, Vaccine, Fine chemical, MD

Results showed that masitinib at 4.5 mg/kg/day can benefit patients by significantly slowing cognitive deterioration relative to placebo.

Key Points: 
  • Results showed that masitinib at 4.5 mg/kg/day can benefit patients by significantly slowing cognitive deterioration relative to placebo.
  • There are very limited treatment options for patients with mild-to-moderate Alzheimer’s disease and to date no approved disease modifying therapy encompasses this later-stage Alzheimer’s disease population.
  • The safety of masitinib as an adjunct to cholinesterase inhibitor and/or memantine was acceptable and consistent with its known tolerability profile.
  • It is noteworthy that this result is in the context of a relative elderly population (average age of about 73 years) with comorbidities.